Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short term Debt (2018 - 2023)

Akebia Therapeutics (AKBA) has disclosed Short term Debt for 4 consecutive years, with $17.5 million as the latest value for Q4 2023.

  • On a quarterly basis, Short term Debt fell 45.31% to $17.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $17.5 million, a 45.31% decrease, with the full-year FY2023 number at $17.5 million, down 45.31% from a year prior.
  • Short term Debt was $17.5 million for Q4 2023 at Akebia Therapeutics, up from $8.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $98.2 million in Q2 2022 to a low of $8.0 million in Q3 2023.
  • A 3-year average of $51.7 million and a median of $32.0 million in 2022 define the central range for Short term Debt.
  • Biggest YoY gain for Short term Debt was 45.31% in 2023; the steepest drop was 87.87% in 2023.
  • Akebia Therapeutics' Short term Debt stood at $97.5 million in 2021, then plummeted by 67.19% to $32.0 million in 2022, then crashed by 45.31% to $17.5 million in 2023.
  • Per Business Quant, the three most recent readings for AKBA's Short term Debt are $17.5 million (Q4 2023), $8.0 million (Q3 2023), and $24.0 million (Q2 2023).